Circulating advanced glycation end products (AGEs) and soluble form of receptor for AGEs (sRAGE) are independent determinants of serum monocyte chemoattractant protein-1 (MCP-1) levels in patients with type 2 diabetes

Diabetes/Metabolism Research and Reviews

Volumn 24, Issue 2, 2008, Pages 109-114

  Nakamura, Kazuo ^a   Yamagishi, Sho Ichi ^a   Adachi, Hisashi ^a   Matsui, Takanori ^a   Kurita Nakamura, Yayoi ^b   Takeuchi, Masayoshi ^a   Inoue, Hiroyoshi ^b   Imaizumi, Tsutomu ^a  

^a KURUME UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^b HOKURIKU UNIVERSITY   (Japan)

Author keywords

AGEs; Atherosclerosis; Diabetes; MCP 1; sRAGE

Indexed keywords

ADIPONECTIN; ADVANCED GLYCATION END PRODUCT; ADVANCED GLYCATION END PRODUCT RECEPTOR; ANTIHYPERTENSIVE AGENT; ANTILIPEMIC AGENT; GLIBENCLAMIDE; GLICLAZIDE; GLIMEPIRIDE; INSULIN; MONOCYTE CHEMOTACTIC PROTEIN 1; PIOGLITAZONE; TUMOR NECROSIS FACTOR ALPHA;

ADULT; AGE DISTRIBUTION; AGED; ANAMNESIS; ANTHROPOMETRY; ARTICLE; ATHEROSCLEROSIS; BLOOD ANALYSIS; CONTROLLED STUDY; DIABETIC NEPHROPATHY; DIABETIC RETINOPATHY; FEMALE; GENDER; HUMAN; INFLAMMATION; JAPAN; MAJOR CLINICAL STUDY; MALE; METABOLIC PARAMETERS; NON INSULIN DEPENDENT DIABETES MELLITUS; OUTPATIENT; PHYSICAL EXAMINATION; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; REGRESSION ANALYSIS; STATISTICAL SIGNIFICANCE;

EID: 39649118422     PISSN: 15207552     EISSN: 15207560     Source Type: Journal    
DOI: 10.1002/dmrr.766     Document Type: Article

References (35)

1. Boyle A. Macrophage activation in atherosclerosis: pathogenesis and pharmacology of plaque rupture. Curr Vasc Pharmacol 2005; 3: 63-68.
2. Rader DJ, Pure E. Lipoproteins, macrophage function, and atheroscleorosis: beyond the foam cell? Cell Metab 2005; 1: 223-230.
3. Gu L, Okada Y, Clinton SK, et al. Absence of monocyte chemoaattractant protein-1 reduces atherosclerosis in low density lipoprotein receptor-deficient mice. Mol Cell 1998; 2: 275-281.
4. Dawson TC, Kuziel WA, Osahar TA, Maeda N. Absence of CC chemokine receptor-2 reduces atherosclerosis in apolipoprotein E-deficient mice. Atherosclerosis 1999; 143: 205-211.
5. Mine S, Okada Y, Tanikawa T, et al. Increased expression levels of monocyte CCR2 and monocyte chemoattractant protein-1 in patients with diabetes mellitus. Biochem Biophys Res Commun 2006; 344: 780-785.
6. Piemonti L, Calori G, Mercalli A, et al. Fasting plasma leptin, tumor necrosis factor-alpha receptor 2, and monocyte chemoattracting protein 1 concentration in a population of glucose-tolerant and glucose-intolerant women: impact on cardiovascular mortality. Diabetes Care 2003; 26: 2883-2889.
7. Kiyici S, Erturk E, Budak F, et al. Serum monocyte chemoattractant protein-1 and monocyte adhesion molecules in type 1 diabetic patients with nephropathy. Arch Med Res 2006; 37: 998-1003.
8. De Lemos JA, Morrow DA, Sabatine MS, et al. Association between plasma levels of monocyte chemoattractant protein-1 and long-term clinical outcomes in patients with acute coronary syndromes. Circulation 2003; 107: 690-695.
9. Vlassara H, Bucala R, Striker L. Pathogenic effects of advanced glycosylation: Biochemical, biologic, and clinical implications for diabetes and aging. Lab Invest 1994; 70: 138-150.
10. Brownlee M. Advanced protein glycosylation in diabetes and aging. Annu Rev Med 1995; 46: 223-234.
11. Dyer DG, Blackledge JA, Thorpe SR, Baynes JW. Formation of pentosidine during nonenzymatic browning of proteins by glucose. J Biol Chem 1991; 18: 11654-11660.
12. Grandhee S, Monnier VM. Mechanism of formation of the Maillard protein cross-link pentosidine. J Biol Chem 1991; 18: 11649-11653.
13. Yamagishi S, Imaizumi T. Diabetic vascular complications: Pathophysiology, biochemical basis and potential therapeutic strategy. Curr Pharm Des 2005; 11: 2279-2299.
14. Ueda S, Yamagishi S, Takeuchi M, et al. oral adsorbent AST-120 decreases serum levels of AGEs in patients with chronic renal failure. Mol Med 2006; 12: 180-184.
15. Takenaka K, Yamagishi S, Matsui T, et al. Role of advanced glycation end products (AGEs) in thrombogenic abnormalities in diabetes. Curr Neurovasc Res 2006; 3: 73-77.
16. Schmidt AM, Stern D. Atherosclerosis and diabetes: the RAGE connection. Curr Atheroscler Rep 2000; 5: 430-436.
17. Schmidt AM, Yan SD, Wautier JL, Stern D. Activation of receptor for advanced glycation end products. A mechanism for chronic vascular dysfunction in diabetic vasculopathy and atherosclerosis. Circ Res 1999; 84: 489-497.
18. Yamagishi S, Nakamura K, Takeuchi M, Imaizumi T. Molecular mechanism for accelerated atherosclerosis in diabetes and its potential therapeutic intervention. Int J Clin Pharmacol Res 2004; 24: 129-134.
19. Gu L, Hagiwara S, Fan O, et al. Role of receptor for advanced glycation end-products and signaling events in advanced glycation end-product-induced monocyte chemoattractant protein-1 expression in differentiated mouse podocytes. Nephrol Dial Transplant 2006; 21: 299-313.
20. Inagaki Y, Yamaagishi S, Okamoto T, Takeuchi M, Amano S. Pigment epithelium-derived factor prevents advanced glycation end products-induced monocyte chemoattractant protein-1 production in microvascular endothelial cells by suppressing intracellular reactive oxygen species generation. Diabetologia 2003; 46: 284-287.
21. Yamagishi S, Inagaki Y, Okamoto T, et al. Advanced glycation end product-induced apoptosis and overexpression of vascular endothelial growth factor and monocyte chemoattractant protein-1 in human-cultured mesangial cells. J Biol Chem 2002; 277: 20309-20315.
22. Nakamura K, Yamagishi S, Adachi H, et al. Elevation of soluble form of receptor for advanced glycation end products (sRAGE) in diabetic subjects with coronary artery disease. Diabetes Metab Res Rev 2007; 23: 368-371.
23. Report of the expert committee on the diagnosis and classification of diabetes mellitus. Diabetes Care 1997; 20: 183-197.
24. Yamagishi S, Adachi H, Nakamura K, et al. Positive association between serum levels of advanced glycation end products and the soluble form of receptor for advanced glycation end products in nondiabetic subjects. Metabolism 2006; 55: 1227-1231.
25. Chiarelli F, Cipollone F, Mohn A, et al. Circulating monocyte chemoattractant protein-1 and early development of nephropathy in type 1 diabetes. Diabetes Care 2002; 25: 1829-1834.
26. Takebayashi K, Matsumoto S, Aso Y, Inukai T. Association between circulating monocyte chemoattractant protein-1 and urinary albumin excretion in nonobese type 2 diabetic patients. J Diabetes Complicat 2006; 20: 98-104.
27. Unoki H, Bujo H, Yamagishi SI, et al. Advanced glycation end products attenuate cellular insulin sensitivity by increasing the generation of intracellular reactive oxygen species in adipocytes. Diabetes Res Clin Pract 2007; 76: 236-244.
28. Li SY, Liu Y, Sigmon VK, McCort A, Ren J. High-fat diet enhances visceral advanced glycation end products, nuclear O-Glc-Nac modification, p38 mitogen-activated protein kinase activation and apoptosis. Diabetes Obes Metab 2005; 7: 448-454.
29. Ajello RJ, Bourassa PA, Lindsey S, et al. Monocyte chemoattractant protein-1 accelerates atherosclerosis in apolipoprotein E-deficient mice. Arterioscler Thromb Vasc Biol 1999; 19: 1518-1525.
30. Inoue S, Egashira K, Ni W, et al. Anti-monocyte chemoattractant protein-1 gene therapy limits progression and destabilization of established atherosclerosis in apolipoprotein E-knockout mice. Circulation 2002; 106: 2000-2007.
31. Miura J, Yamagishi S, uchigata Y, et al. Serum levels of non-carboxymethyllysine advanced glycation endproducts are correlated to severity of microvascular complications in patients with Type 1 diabetes. J Diabetes Complicat 2003; 17: 16-21.
32. Bolton WK, Cattran DC, Williams ME, et al. Randomized trial of an inhibitor of formation of advanced glycation end products in diabetic nephropathy. Am J Nephrol 2004; 24: 32-40.
33. Tan KCB, Shiu SW, Chow WS, et al. Association between serum levels of soluble receptor for advanced glycation end products and circulating advanced glycation end products in type 2 diabetes. Diabetologia 2006; 49: 2756-2762.
34. Park L, Raman KG, Lee KJ, et al. Suppression of accelerated diabetic atherosclerosis by the soluble receptor for advanced glycation end products. Nat Med 1998; 4: 1025-1031.
35. Humpert PM, Djuric Z, Kopf S, et al. Soluble RAGE but not endogenous secretory RAGE is associated with albuminuria in patients with type 2 diabetes. Cardiovasc Diabetol 2007; 6: 9, Doi:10.1186/1475-2840-6-9.